Search
for
Sort by
Research 30 of 1000+
- Targeting the Janus Kinase Family in Autoimmune Skin Diseases
- Efficacy, Safety, and Real-World Aspects of Janus Kinase Inhibitors to Treat Patients With Alopecia Areata
- The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases
- Frontal fibrosing alopecia shows robust T helper 1 and Janus kinase 3 skewing
- Comparative efficacy of oral Janus kinase inhibitors and biologics in adult alopecia areata: A systematic review and Bayesian network meta‐analysis
- Unexpected Hair Regrowth in a Patient with Longstanding Alopecia Universalis During Treatment of Recalcitrant Dermatomyositis with the Janus Kinase Inhibitor Ruxolitinib
- 544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1)
- Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions
- The Role of Janus Kinase Inhibitors in Dermatology
- Janus Kinase Inhibitors - A next generation treatment in Dermatology
- Janus kinase inhibitors: An innovative treatment for alopecia areata
- The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature
- Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature
- Janus Kinase Inhibitors in Dermatology: Part 1 — General Considerations and Applications in Vitiligo and Alopecia Areata
- The role of janus kinases in the treatment of autoimmune skin diseases
- Janus kinase inhibitors for alopecia areata: a review of clinical data
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- The JAK/STAT signaling pathway: from bench to clinic
- Dermal T cell immunity and key regulatory signaling pathways: Implications in immune-mediated alopecia and hair regeneration
- Precision therapeutics in non-scarring alopecia: a systemic genomic and pathway-based framework for targeted interventions
- Hair growth–promoting effects of Enz_MoriL on human dermal papilla cells through modulation of the Wnt/β-Catenin and JAK-STAT signaling pathways
- Translational Positioning of Janus Kinase (JAK) Inhibitors in Alopecia Areata
- Baricitinib for the Treatment of Alopecia Areata
- Under Development JAK Inhibitors for Dermatologic Diseases
- FDA approval of Deuruxolitinib: A New Treatment Option for Severe Alopecia Areata
- JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis
- Functional Interpretation of Genome-Wide Association Study Evidence in Alopecia Areata
- New drugs under investigation for the treatment of alopecias
- Brazilian Experience of the Treatment of Alopecia Universalis with the Novel Antirheumatic Therapy Tofacitinib: A Case Series
- Alopecia areata – Current understanding and management